• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Press Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

Press Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks

by Adam | Mar 27, 2020 | News

March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen...
Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

Press Release: eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

by Adam | Mar 24, 2020 | News

March 24, 2020 Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and...
Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding – WPRI News Channel 12 interview

by Adam | Mar 20, 2020 | News

Providence-based EpiVax developing 2 coronavirus vaccines, needs more funding by: Sarah Doiron, Logan Wilber Posted: Mar 19, 2020 / 06:00 PM EDT / Updated: Mar 19, 2020 / 06:33 PM EDT Find the full story here. PROVIDENCE, R.I. (WPRI) ─ As the country races to stem the...
Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

Providence biotech company working to create coronavirus vaccine – Providence NBC 10 News interview

by Adam | Mar 20, 2020 | News

Providence biotech company working to create coronavirus vaccine by TAMARA SACHARCZYK, NBC 10 NEWS Wednesday, March 18th 2020 Find the full story here EpiVax in Providence. (WJAR) A team of local scientists are on the front lines of a global pandemic as they race...
Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

Press Release: Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic

by Adam | Mar 4, 2020 | News

March 04, 2020 09:00 ET | Source: Generex Biotechnology Corporation MIRAMAR, Fla., March 04, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (https://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the...
« Older Entries
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.